Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Cyclacel Pharmaceuticals, Inc. (CYCC) had Normalized Pre-Tax Income of $-1.32M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-1.34M |
|
-- |
|
-- |
|
$1.32M |
|
$-1.32M |
|
$0.00M |
|
$-1.32M |
|
|
Normalized Pre-Tax Income |
$-1.32M |
$-1.32M |
|
$-1.32M |
|
$-1.32M |
|
$-1.32M |
|
$-1.32M |
|
$-1.32M |
|
1.37M |
|
1.37M |
|
$-0.98 |
|
$-0.98 |
|
| Balance Sheet Financials | |
$4.38M |
|
$0.00M |
|
$0.02M |
|
$4.40M |
|
$0.76M |
|
-- |
|
$0.01M |
|
$0.77M |
|
$3.63M |
|
$3.63M |
|
$3.63M |
|
1.58M |
|
| Cash Flow Statement Financials | |
$-4.30M |
|
-- |
|
$5.53M |
|
$3.14M |
|
$4.28M |
|
$1.14M |
|
$1.67M |
|
-- |
|
$-0.04M |
|
| Fundamental Metrics & Ratios | |
5.77 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-4.30M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-36.33% |
|
-36.30% |
|
-29.95% |
|
-36.30% |
|
$2.29 |
|
$-3.15 |
|
$-3.15 |
|